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Abstract 
Study Objective: Heavy menstrual bleeding (HMB) is a common gynaecological complaint 
among young females with up to 40% having experienced HMB. Bleeding disorders are 
increasingly being recognised in adolescents and young adults with HMB. The aim of this 
study was to determine the prevalence of bleeding disorders in adolescents with HMB, 
among patients presenting to the Queensland Statewide Paediatric and Adolescent 
Gynaecology (PAG) Service between July 2007 to July 2017. 
Design, Settings, Participants, Interventions, and Main Outcome Measures: The study was a 
retrospective review of 124 adolescent females aged 8 to 18 years with HMB presenting to 
the Queensland PAG Service, Brisbane, Australia. The primary outcome measure was 
diagnosis of a bleeding disorder, with secondary outcomes including iron deficiency and/or 
anaemia and treatment modalities.  
Results: Screening for bleeding disorders was performed in 62.1% (77/124) of patients with 
HMB.  Twenty-seven adolescents were diagnosed with a bleeding disorder, giving a 
prevalence of 21.7% (27/124) in those with HMB, and 35% (27/77) with HMB that were 
screened. Of these 35%, von Willebrand Disease (VWD) was the most common bleeding 
disorder, found in 51.6% (14/27), followed by inherited platelet function disorders 
diagnosed in 33.3% (9/27), thrombocytopenia (inherited or acquired) in 11.1% (3/27), and 
Factor IX deficiency in 3.7% (1/27). Iron deficiency and/or anaemia was diagnosed in 49.5% 
(53/107) of patients with HMB that were screened for this, and 70.3% (19/27) of those 
diagnosed with a bleeding disorder.  
Conclusion: Adolescents with HMB presenting to a tertiary PAG service should be screened 
for bleeding disorders, given the considerably high prevalence in this at-risk population.   
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Introduction 
Heavy menstrual bleeding (HMB) is a common gynaecological complaint among adolescents 
with up to 40% having experienced HMB. [1]  In many cases, immaturity of the 
hypothalamic-pituitary-ovarian axis, leading to anovulatory cycles, is thought to be the 
underlying cause for heavy menses. However, in young women with HMB, particularly in 
those who are presenting with anaemia and those who are not responding to the usual 
hormonal attempts to manage HMB, it is prudent to consider the presence of an underlying 
bleeding disorder.  
 
Bleeding disorders are increasingly being recognised in women with HMB, and several 
studies have shown that 10 – 62% of adolescents with HMB have an underlying bleeding 
disorder. [2, 3, 4] These studies show the prevalence of Von Willebrand’s Disease (VWD) to 
be 5 - 36%, platelet function disorders (PFD) to be 2 - 44%, thrombocytopenia to be 13-20%, 
and clotting factor deficiencies to be 8-9%. [5,6]  
 
The aim of this study was to determine the prevalence of bleeding disorders in adolescents 
with HMB presenting to a tertiary hospital Paediatric and Adolescent Gynaecology (PAG) 
service. 
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Methods 
This study was a retrospective review of all patients with HMB that presented to the 
Queensland Paediatric and Adolescent Gynaecology (PAG) Service from July 2007 to July 
2017. Ethics approval was obtained from the Royal Brisbane and Women’s Hospital Human 
Research Ethics Committee (HREC/17/QRBW/488). All patients coded on our database 
presenting with menstrual disorders were identified, and the medical records of those with 
HMB were reviewed.  Data was collected on patient demographics, clinical history and 
symptoms, pathology results, therapeutic regimens, outcomes and follow up. SPSS version 
22 (IMB Corp) was used for all analysis.  
 
Clinical and laboratory findings from patients with bleeding disorders were independently 
reviewed by a Specialist Paediatric Haematologist to ensure that patients were classified in 
accordance with recognised International criteria.  The difficulty in accurately diagnosing 
mild Type 1 VWD has been well described, presenting classification challenges in both the 
clinical and research spheres. [6, 7] For the purposes of this study, and in keeping with 
recent British guidelines, Type 1 VWD was classified as a positive bleeding and/or family 
history with reduced VWF:Ag and VWF:RCo, where either VWF:Ag or VWF:RCo was <0.3 U 
mL
−1   
with a Rco:Ag ratio of >0.6. “Low VWF” was classified as a positive bleeding history 
and/or family history with VWF:Ag and VWF:RCo levels of 0.30–0.49 U mL
−1
. Criteria for 
classification of subtypes of type 2 VWD and type 3 VWD were in keeping with recent 
published guidelines. [9] Platelet function disorders were classified by the Haematologist in 
keeping with recognised diagnostic criteria according to blood film findings, platelet 
aggregation studies (light transmission aggregometry) and platelet electron microscopy 
findings. [10] Dense body (granule) deficiency was specifically defined as a dense granule 
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count of 2.5 or less by electron microscopy [10], replicated on two occasions (according to 
locally established protocols).  Where there was a clearly abnormal bleeding history and 
abnormally prolonged automated platelet function testing (PFA-100) without other cause, 
but definitive platelet function testing had not been performed, the temporary designation 
was “possible platelet function disorder”. Haemophilia A or B was classified according to 
factor VIII or factor IX levels of < 1 – 40% respectively, with severe < 1%, moderate 1 – 5% 
and mild 5 – 40%. Known carriers of Haemophilia A or B who had a factor VIII or IX level of 
40 - 60% respectively, and a bleeding history, were designated as symptomatic carriers of 
Haemophilia A or B. [11]  
 
Results  
One hundred and twenty-four (124) adolescents presented with HMB from a total cohort of 
635 adolescents referred to the PAG service over the study time for a multitude of 
gynaecological conditions (Figure 1). The median age of adolescents with HMB was 14 years 
and 3 months (range 10 years and 9 months to 18 years and 5 months). Screening for 
bleeding disorders was performed in 62.1% (77/124) of all patients presenting with 
HMB.  Overall, 21.7% (27/124) of all patients with HMB, and 35% (27/77) of those screened 
had a bleeding disorder. VWD was the most common bleeding disorder and diagnosed in 
51.6% (14/27) [Figure 2]. Of these, 6 adolescents were classified as low VWF and 8 
adolescents were classified as Type 1 VWD. There were no patients in this study with rarer, 
more severe forms of VWD, such as type 2 or type 3 VWD. Platelet function disorders were 
detected (or strongly suspected) in 33.3% (9/27), of which dense body deficiency was the 
most common form confirmed, found in 4 adolescents. Thrombocytopenia was diagnosed in 
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11.1% (3/27), of which 2 were acquired (immune thrombocytopenia) and 1 were inherited. 
Factor IX deficiency (Symptomatic carrier of Haemophilia B) was diagnosed in 3.7% (1/27).  
 
Iron deficiency and/or anaemia was screened for in 86.3% (107/124) and diagnosed in 
49.5% (53/107) of those screened.  In the 27 cases that had been diagnosed with a bleeding 
disorder, 70.3% (19/27) were iron deficient and/or anaemic, and 7.4% or 2 patients required 
a blood transfusion for anaemia.  
 
In patients with bleeding disorders, hormonal therapies were prescribed in 96% (26/27) of 
patients. Several patients were treated with more than one treatment modality, 
simultaneously or consecutively. The combined oral hormonal pill was used in 62% (17/27), 
Medroxyprogesterone, either orally or in Depot form in 26% (7/27), and LNG-IUS (Mirena, 
Bayer) in 30% (8/27). Tranexamic acid, an antifibrinolytic agent, was utilised in 87% of all 
patients with a bleeding disorder. Iron replacement was required in 70% (19/27) of 
patients.  It was uncommon for targeted haemostatic therapies such as Desmopressin and 
factor concentrates to be required for HMB, and these were prescribed under the 
supervision of the treating haematologist. Acute surgical management for heavy menstrual 
bleeding was not required in any case, as all cases were able to be managed with medical 
management.   
 
Discussion  
The findings of this study would suggest that adolescents presenting with HMB, and/or 
anaemia to a tertiary centre should be further evaluated for a bleeding disorder, including a 
thorough bleeding and family history and laboratory haemostatic 
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investigation.   Adolescents referred to the paediatric and adolescent gynaecologist are 
likely to be a higher risk population for bleeding disorders. They are more likely to have had 
a prior review in the primary care or general gynaecology setting, and may have been non-
responsive to usual first line management for HMB. The adolescent with heavy menses and 
iron deficiency anaemia may be affected by fatigue, be spending less time on enjoyable 
activities such as sport, absence from school, and be have difficulty concentrating and 
performing schoolwork. [12] Early diagnosis of a bleeding disorder may assist to reduce 
morbidity and suffering from HMB in the adolescent period, but importantly it will identify 
those at increased risk for long term complications such as surgical or obstetric 
haemorrhage. Published data shows that 8 - 18% of women with a bleeding disorder will 
proceed to have surgery for HMB, including for management of haemorrhagic ovarian cysts 
or hysterectomy. An undiagnosed bleeding disorder may pose a greater risk of 
complications in these women. [13]   
 
Screening 
A systematic and stepwise haemostatic evaluation in young women presenting with HMB 
should be undertaken. A comprehensive bleeding history is critical and should include 
detailed questioning regarding the presence of abnormal bruising, mucosal bleeding 
(epistaxis and oral bleeding), post-surgical and post-dental procedure bleeding and bleeding 
after minor trauma. There is a wide spectrum of minor bleeding reported by healthy 
individuals and it can be difficult to be definitive around what constitutes a history of 
‘abnormal bleeding’. Screening tools, such as Pictorial Blood Assessment Charts (PBAC), may 
be of assistance in quantifying the amount of bleeding the adolescent is experiencing. [14]  
The use of validated bleeding assessment tools (BATs) are increasingly being used in clinical 
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Haematology practice to assist in identifying individuals with a bleeding history that is 
abnormal and predictive of an underlying bleeding disorder.  Whilst there are paediatric 
specific BATs (the Paediatric Bleeding Questionnaire [15, 16] and ISTH-BAT [17]), these BATs 
still lack sensitivity, efficiency and flexibility in the paediatric and adolescent setting. [18]  It 
should be noted that these younger patients are less likely to have had significant surgical 
challenges compared to their adult counterparts and therefore (apart from menstruation) 
have had fewer opportunities for a bleeding disorder to become manifest. The limitations of 
currently available paediatric BATs are recognised and newer BATs are in development that 
will hopefully address these deficiencies. [19]   
 
Investigation 
Initial laboratory testing as outlined in Figure 3 should reasonably include a full blood count 
and examination of the blood film, prothrombin time (PT), activated patient thromboplastic 
time (APPT), clottable (Clauss) fibrinogen, and von Willebrand screen (including a factor VIII 
level, VWF:Antigen,  VWF:Ristocetin cofactor activity and VWF: Collagen binding assay. An 
automated platelet function analysis test (PFA-100) may also be considered as part of the 
general screen. Where a family history of a clotting factor deficiency is present or where the 
initial screening coagulation profile is abnormal then additional factor levels will be required 
in consultation with the Haematologist. It should be noted that despite Haemophilia A and B 
being X-linked recessive disorders, that approximately 20% of female carriers do have 
reduced factor VIII or IX levels (due to skewed lyonization) and that this can lead to 
problematic menstrual bleeding. [20] 
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Where initial testing is normal but the clinical history is suggestive of a bleeding disorder or 
where HMB is persistent (without other gynaecological or endocrine cause) then more 
detailed haemostatic investigation is warranted in consultation with the Haematologist. 
Disorders of platelet function requires specialised platelet aggregometry (+/- electron 
microscopy and platelet glycoprotein flow cytometry) testing and such investigations can 
usually only be performed in a tertiary haemostatic laboratory. It is important to note that 
automated platelet function testing (for example the PFA-100) is not considered diagnostic 
of a platelet function disorder as it is subject to considerable pre-analytical variables, and 
abnormal results may be encountered simply due to transport artefact or medication use, 
particularly non-steroidal anti-inflammatory drugs. The PFA-100 test is also not sensitive to 
mild disorders of platelet function. [21]  
 
Due to the many pre-analytical variables that can impact on the haemostatic system 
investigations (particularly VWF levels and platelet aggregometry) it is not uncommon for 
repeat investigations to be required before a diagnosis can be confirmed.  Accurate 
subclassification of type 2 VWD will also require further specialized testing including a 
Ristocetin induced platelet aggregation (RIPA) test. [22] The repeated testing to establish a 
formal diagnosis may prove frustrating for children and their families in some situations.   
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Diagnosis 
The challenge of making an accurate diagnosis of mild type 1 VWD also exists in this group, 
as mildly reduced VWF levels of 40-50% are a relatively common finding that may well 
improve with age and are not themselves diagnostic of type 1 VWD. We had incomplete 
blood group data for our cohort, however it is well described that individuals who are blood 
group 0 often have VWF levels that are <0.5 U/ml and this laboratory finding may not clearly 
segregate with a bleeding or family history. [23] There is some controversy in the literature 
regarding the testing for VWD in patients already on the combined hormonal oral pill. From 
the best available evidence, it is not necessary to discontinue these to investigate for VWD, 
as VWF Ag, Factor III, and Ristocetin cofactor parameters are not affecting by combined 
hormonal pills. [24]  
Given the propensity for borderline levels to resolve with age, for patients with borderline 
low VWF levels it may be more appropriate to use the term “low VWF” rather than labelling 
a young adolescent with a disease. Patients with low VWF can be considered to have a risk 
factor for bleeding, rather than a disorder and their bleeding history and VWF levels can be 
followed up over time as many will never meet the criteria for formal diagnosis of VWD. [8] 
We did not diagnose any rarer forms of VWD (type 2 or type 3) in our cohort, likely 
reflective of both their comparatively lower prevalence and the higher likelihood that these 
(more severe) disorders would have already become apparent prior to onset of 
menstruation due to the manifestation of other bleeding symptoms. 
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Rare factor deficiencies are occasionally found in girls presenting with refractory HMB. 
Factor II, V and X deficiency would be suspected due to prolongation of both the APTT and 
PT (see diagram), and factor VII deficiency by prolongation of the PT. It should be noted that 
mild intrinsic pathway deficiencies (factor VIII, IX, XI) may not always prolong the APTT, and 
if suspected from the family or clinical history these should be specifically requested.  Factor 
XIII deficiency does not alter the coagulation profile, however it is extremely rare and should 
only be tested where HMB is occurring in conjunction with other unexplained significant 
bleeding symptoms. [25]  
 
Management 
Institution of appropriate long-term management of menses in adolescents with bleeding 
disorders will be of considerable benefit in preventing morbidity.  With mild bleeding 
disorders causing chronic heavy menstrual bleeding, the combined oral hormonal pill, 
progesterone only hormonal options, and antifibrinolytics are considered first-line 
treatment [26, 27, 28].  In our institution, it would be routine to present all of the hormonal 
and non-hormonal options, screen for contraindications, and then allow the adolescent and 
parent/caregiver to make an informed choice after counselling. 
 
Estrogen-containing oral contraceptive medications are effective in reducing the frequency 
and duration of menstrual periods. Administration of a combined pill containing 30 mcg 
ethinyl oestradiol diminishes the secretion of luteinizing hormone and follicle-stimulating 
hormone from the pituitary, thereby inhibiting ovulation and leading to stabilization of the 
endometrial surface of the uterus [29]. Alternative routes of administration of combined 
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estrogen and progesterone preparations are transdermal preparations and vaginal rings, 
however these but not in widespread use in Australia in the adolescent population, and 
have not been investigated in the adolescent bleeding disorder population.   
 
If there are contraindications to the use of estrogen containing preparations, or patient 
preference is for a progesterone only method, we would commonly offer either cyclical 
Medroxyprogesterone acetate 20-40mg oral once daily for 21 days each month, or if the 
goal is menstrual suppression, Depot Medroxyprogesterone acetate 150mg every 12 weeks.  
We have found the LNG-IUS to be a highly effective at achieving menstrual suppression in 
adolescents with bleeding disorders, with 30% of our cohort proceeding to insertion of 
Mirena IUS.  At our institution we would routinely offer this as a treatment modality for all 
adolescents with HMB, with insertion under GA, as the safety in the adolescent population 
has been well established. [30] 
 
Tranexamic acid (TEXA) is an anti-fibrinolytic agent that may be used alone or in conjunction 
with hormones, and is highly effective at reducing menstrual bleeding in patients with 
bleeding disorders. TEXA was used in up to 87% of adolescents with bleeding disorders in 
this cohort. It competitively inhibits the activation of plasminogen to plasmin, and at higher 
concentrations, is a non-competitive inhibitor of plasmin. [31] Typically, TEXA is dosed 
intermittently for HMB, with our usual protocol being a 15-25mg per kg per dose (maximum 
1.5 grams) given orally three times a day, for days 1 to 4 of the menstrual cycle.  
Aminocaproic acid (Amicar) is an alternative antifibrinolytic, however, it is not currently 
marketed in Australia. We typically prescribe TEXA in conjunction with progesterone only 
preparations, such as Medroxyprogesterone or Norethisterone, rather than oestrogen 
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containing combined pills, as the use of estrogen in addition TEXA, may pose a greater risk 
of venous thromboembolism. 
 
Acute Haemorrhage  
In cases involving acute haemorrhage, hospitalization and/or blood transfusions may be 
required.  It is interesting to note that blood transfusion was required very rarely in our 
cohort of adolescents with HMB and an underlying bleeding disorder. This may reflect the 
prompt recognition of iron deficiency and early aggressive management with appropriate 
iron therapy in our cohort whilst working to control underlying HMB with hormonal and 
antifibrinolytic therapy. The well-established “restrictive transfusion policy” at our centre 
may have also contributed to the low blood transfusion rate observed.  
 
There are various hormonal regimes that can be used (Table 1), however the data in the 
literature specifically comparing the effectiveness of various modalities in specifically in 
adolescents with bleeding disorders with acute heavy bleeding is limited. Estrogen may be 
given intravenously, 25mg IV every 4-6 hours, or alternatively in the form of a 30-50 mcg 
ethinyl oestradiol combined pill 1 tablet every 6 hours, until bleeding ceases, which in most 
cases occurs within 24 hours of treatment. Alternatively, progesterone only treatments are 
available and have been shown to be effective. At our institution, for heavy acute bleeding 
we would commence Medroxyprogesterone acetate 10-20mg every 6 to 8 hours, or 
Norethisterone 5 -10 mg every 8 hours.  Once bleeding has settled, tapering of the 
hormonal therapies will be required, and there are various protocols regimes for weaning to 
a maintenance does of hormonal therapies exist [28].  Additionally, in the setting of acute 
heavy bleeding, tranexamic acid may be given at a dose of 1g by intravenous injection over 
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10 minutes, followed by oral administration as per protocol described above. Surgical 
interventions such as dilatation and curettage, and or insertion of 30cc Foley Catheter 
balloon is only very rarely required when prompt medical management is instituted.  
 
 
Targeted therapy  
Accurate and early recognition of bleeding disorders in the adolescent is critical for 
management of future severe bleeding episodes that may benefit from directed therapies, 
preoperative prophylaxis and treatment of surgical haemorrhage, including future 
preparation for obstetric related bleeding.  For patients with mild to moderate VWD type 1, 
mild haemophilia A, some patients with type 2A and type 2M VWD and some mild platelet 
function disorders, Desmopressin (a synthetic vasopressin analogue) can be used.  In 
Australia this is available in subcutaneous and intravenous preparations, and in some 
countries, in nasal preparations. Desmopressin stimulates the release of endothelial VWF, 
thereby increasing the levels of VWF, and enhancing platelet adhesion to the vessel wall. 
[32] Desmopressin is generally reserved for refractory HMB that has not responded to anti-
fibrinolytic and multiple hormonal approaches. Caution with fluid restriction to two-thirds 
maintenance for 24 hours after each dose is imperative to prevent hyponatremia.  [33] 
Severe forms of VWD require clotting factor concentrates containing VWF for treatment (or 
rarely prevention) of haemorrhages.  
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Iron replacement 
Iron deficiency and/or anaemia contributes to morbidity seen in this population, and this 
study has demonstrated a high prevalence of iron deficiency and/or anaemia.  Adolescents 
with heavy menstrual bleeding should therefore be screened for iron deficiency anaemia, 
and appropriate treatment instituted. It is very important to be very specific when 
prescribing oral iron replacement as there exist many over the counter supplements which 
have very low content of iron and provide little benefit (Table 2). We routinely recommend 
a combined iron formulation such as Ferrograd C containing ferrous sulfate 325mg 
(equivalent to 105mg of elemental iron) and Sodium ascorbate (equivalent to 500mg or 
ascorbic acid or Vitamin C) for improved absorption, at a dose of one tablet daily. The 
availability of newer, safer, more cost effective intravenous iron preparations (iron 
carboxymaltose, Ferinject) and generally unfavourable side effect profile of oral 
preparations may lower the threshold for replacing iron intravenously. Ferinject is given at a 
maximum single dose of up to 1000mg as an intravenous infusion over 15 minutes, which 
may be repeated a week later, according to the Ganzoni formula. [34]  
 
Limitations and Strengths 
The retrospective nature of this cohort study meant that HMB was not able to be objectively 
measured, which is a limitation encountered by other groups investigating HMB and reflects 
the challenges in trying to design and carry out prospective studies in the field of adolescent 
menstruation. The research was carried out in a tertiary care centre and by virtue of a 
referral pattern reflecting more refractory cases of HMB, it is almost certain that the 
prevalence of bleeding disorders in the population has been overestimated compared to 
that seen in studies from a primary care setting. A strength of this study is that all patients 
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were reviewed and classified according to standardized criteria by a specialist Paediatric 
Haematologist.  
 
Conclusion 
Our data is consistent with international published literature that shows that a large 
proportion of adolescent girls with HMB referred to a tertiary PAG clinic will have an 
underlying bleeding disorder.  It is likely that a high proportion of adolescents with HMB 
presenting in the primary setting may also be underrecognized and untreated, and thus 
there should be a low threshold to recognise, screen and treat.  
 
These findings support comprehensive and systematic haemostatic evaluation in 
adolescents with HMB.  A higher level of awareness of bleeding disorders as a cause for 
HMB in adolescence, especially VWD and platelet function disorders, is needed and close 
multidisciplinary collaboration between the paediatric and adolescent gynaecologist and 
haematologist in a specialised tertiary centre should be established in the management of 
these patients. Effective management can be accomplished with either hormonal 
medications alone or in conjunction with antifibrinolytic agents in the majority of 
patients.   In adolescents who are already known to have a bleeding disorder, consultation 
with a paediatric gynaecologist and/or haematologist prior to menarche may be helpful to 
outline abnormal patterns of menstrual bleeding and to discuss options of treatment in the 
event of HMB. 
 
Disclosure/Conflict of Interest Statement 
The authors do not have any conflicts of interest to disclose.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
References 
1. Friberg B, Orno AK, Lindgren A, Lethagen S: Bleeding disorders among young women: a 
population-based prevalence study. Acta Obstet Gynecol Scand 2006; 85: p. 200. 
2. Ahuja SP, Hertweck SP: Overview of bleeding disorders in adolescent females with 
menorrhagia. J Pediatr Adolesc Gynecol 2010; 23(6 Suppl.): S15–21. 
3. Chi C, Pollard D, Tuddenham EG, et al: Menorrhagia in adolescents with inherited 
bleeding disorders. J Pediatr Adolesc Gynecol 2010; 23: p. 215. 
4. Vo KT, Grooms L, Klima J, et al: Menstrual bleeding patterns and prevalence of bleeding 
disorders in a multidisciplinary adolescent haematology clinic. Haemophilia 2013; 19: p. 
71. 
5. Mills HL, Abdel-Baki MS, Teruya J, Dietrich JE, Shah MD, Mahoney D, Yee DL, Srivaths LV: 
Platelet function defects in adolescents with heavy menstrual bleeding. Haemophilia 
2014; 20 (2): p. 249. 
6. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA: Frequency of inherited bleeding 
disorders in women with menorrhagia. Lancet 1998; 14: 351: p. 485. 
7. Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, O’Connell NM, et 
al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF 
levels. Blood 2017. 130(21): p. 2344-2353. 
8. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003. 
101(6): p. 2089-93. 
9. Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A, Millar CM, Keeling DM. 
The diagnosis and management of von Willebrand disease: a United Kingdom 
Haemophilia Centre Doctors Organization guideline approved by the British Committee 
for Standards in Haematology. Br J Haematol 2014. 167(4): p. 453-65. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10. Gresele P. Diagnosis of inherited platelet function disorders: guidance from the SSC of 
the ISTH. J Thromb Haemost 2015. 13(2): p. 314-22. 
11. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlan CA, 
et al. Guidelines for the management of hemophilia. Haemophilia 2013. 19(1): p. e1-47. 
12. Wang W, Bourgeois T, Klima J, et al: Iron deficiency and fatigue in adolescent females 
with heavy menstrual bleeding. Haemophilia 2012; 19:225. 
13. James AH. More than menorrhagia: a review of the obstetric and gynaecological 
manifestations of bleeding disorders. Haemophilia 2005; 11: 295. 
14. Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial 
chart. Br J Obstet Gynaecol 1990; 97: 734–9.  
15. Bidlingmaier C, Grote V, Budde U, Olivieri M, Kurnik K. Prospective evaluation of a 
pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and 
parents in routine clinical practice. J Thromb Haemost 2012. 10(7): p. 1335-41. 
16. Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the 
diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J 
Thromb Haemost 2009. 7(8): p. 1418-21. 
17. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D.  
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a 
new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010. 8(9): p. 
2063-5. 
18. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb 
Haemost 2012. 10(11): p. 2223-9. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19. Stokhuijzen E, Rand ML, Cnossen MH, Biss TT, James PD, Suijker MH, Peters M, et al. 
Identifying Children with Hereditary Coagulation disorders (iCHEC): a protocol for a 
prospective cohort study. BMJ Open 2018. 8(5): p. e020686. 
20. Boban A, Lambert C, Lannoy N, Hermans C. Comparative study of the prevalence of 
clotting factor deficiency in carriers of haemophilia A and haemophilia B. Haemophilia 
2017. 23(5): p. e471-e473. 
21. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. Guidelines for 
the laboratory investigation of heritable disorders of platelet function. Br J Haematol 
2011. 155(1): p. 30-44. 
22. Frontroth JP, Favaloro EJ. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA 
Mixing Studies. Methods Mol Biol 2017. 1646: p. 473-494. 
23. Albanez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, Lillicrap D. Aging and 
ABO blood type influence von Willebrand factor and factor VIII levels through 
interrelated mechanisms. J Thromb Haemost 2016. 14(5): p. 953-63. 
24. Dumont T, Allen L, Kives S. Can von Willebrand Disease Be Investigated on Combined 
Hormal Contraceptives? J Pediatr Adolesc Gynecol 2013. 26 (3): p. 138-41. 
25. Bolton-Maggs PH. The rare inherited coagulation disorders. Pediatr Blood Cancer 2013. 
60 Suppl 1: p. S37-40. 
26. Alaqzam TS, Stanley AC, Simpson PM, Flood VH, Menon S. Treatment Modalities in 
Adolescents Who Present with Heavy Menstrual Bleeding. J Pediatr Adolesc Gynecol 
2018. 31(5): p. 451-458. 
27. Powers JM, Stanek JR, Srivaths L, Haamid FW, O’Brien SH. Hematological Considerations 
and Management of Adolescent Girls with Heavy Menstrual Bleeding and Anemia in US 
Children’s Hospitals. J Pediatr Adolesc Gynecol 2018. 31(5): p. 247-250. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28. Haamid F, Sass AE, Dietrich JE. Heavy Menstrual Bleeding in Adolescents. NASPAG 
Committee Opinion. J Pediatr Adolesc Gynecol 2017. 30(3): p. 335-340. 
29. Reproductive Endocrinology. In: Hoffman B, Schorge J, Bradshaw K, Halvorson L, Schaffer 
J, Corton M. Williams Gynaecology. 2016 3
e, 
New York, NY: McGraw-Hill, Section 2, 
Chapter 17; Section ID 118170024.  Accessed August 22, 2018. 
30. Adeyemi-Fowode OA, Santos XM, Dietrich JE, SrivathL. Levonorgestrel-Releasing 
Intrauterine Device Use in Female Adolescents with Heavy Menstrual Bleeding and 
Bleeding Disorders: Single Institution Review. J Pediatr Adolesc Gynecol 2017. 30(4): 
p479-483. 
31. Bryant-Smith A, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual 
bleeding. Cochrane Database Syst Rev, 2018. 4: p. CD000249. 
32. Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin 
(DDAVP) in the management of patients with congenital bleeding disorders. 
Haemophilia 2014. 20(2): p. 158-67. 
33. Mason JA, Robertson JD, McCosker J, Williams BA, Brown SA. Assessment and validation 
of a defined fluid restriction protocol in the use of subcutaneous desmopressin for 
children with inherited bleeding disorders. Haemophilia 2016. 22(5): p. 700-5. 
34. Baird-Gunning J, Bromley J. Correcting iron deficiency. Aust Prescr 2016. 39(6): p.193-
199. 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1: Medical and hormonal Therapies for Acute Heavy Menstrual bleeding 
 
 
Therapy Dose Route Initial Frequency 
 
Conjugated oestrogen 
 
25 mg IV Every 4 -6 hours 
 
50 mcg ethinyl oestradiol 
combined pill 
1 tablet Oral Every 6 hours 
 
30 mcg ethinyl oestradiol 
combined pill 
1 tablet Oral Every 6 hours 
 
Medroxyprogesterone  
 
10-20mg 
 
Oral 
 
Every 6 to 8 hours 
 
Norethisterone  
 
5-10mg 
 
Oral  
 
Every 8 hours 
Tranexamic acid 
 
1g 
 
 
Intravenous 
 
 
One dose over 10 
minutes 
 
Tranexamic acid 
15-25mg per kg per dose 
(max 1.5 g) 
Oral Every 8 hours 
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Table 2: Commonly available Oral Iron preparations  
 
 
 
Brand name Formulation Elemental Iron content 
Ferro-gradumet 
 
Ferrous sulfate 325mg 
Controlled-release tablets 
 
105mg 
Ferrograd C 
 
Ferrous sulfate 325mg 
Vitamin C 500mg 
Controlled-release tablets 
 
105mg 
 
Ferro-tab Ferrous fumarate 200mg 65.7mg 
Ferro-liquid Ferrous Sulfate 30mg/ml 6mg/ml 
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Figure 1: Prevalence of Bleeding Disorders in patients with Heavy Menstrual Bleeding 
Presenting to Queensland PAG Service. 
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Figure 2: Classification of Bleeding Disorders in Adolescents with HMB. 
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Figure 3: Tiered approach to the laboratory Investigation of Adolescents with HMB 
 
 
 
 
 
1st line 
investigations
• Full blood count, Iron studies, bhcg, TSH, T4
• APPT, PT, fibrinogen. 
• von Willebrand screen (VIII level, VWF:Antigen, VWF:Ristocetin 
cofactor activity, VWF:Collagen binding assay)
• Plateleft function analasis
Specialised 
Haematology 
Investigations
• Factor levels (as directed by Family hx or coagulation profile)
• Platelet aggremometry
• Electron microscopy
• Platelet glycoprotein flow cytology
